Join us on November 16 for IDEAYA’s Investor R&D Day in London and virtually where our team will be presenting the progress being made in our precision medicine pipeline.
Register: https://t.co/cEyilyCMY6 #PrecisionMedicine
New peer-reviewed results from the Phase 2 OptimUM-01 study have been published in the @ASCO@JCO_ASCO.
Read the publication: https://t.co/1uUVJxevn8
#UvealMelanoma
As #ESMO26 concludes, we’re energized by the scientific insights and collaboration shared across the oncology community.
We’re proud of the IDEAYA team whose expertise and dedication brought our presence in Madrid to life.
Learn more: https://t.co/yFqm2pCjMd
#PrecisionOncology
At #ESMO26, our partner Hengrui Pharma will present long-term Phase 1 results for IDE849 (SHR-4849), an investigational DLL3-targeting ADC, in relapsed SCLC and other NECs.
Explore IDEAYA’s broader ADC+DDR strategy: https://t.co/dg9FjuLNAW
At #ESMO26, OptimUM-01 and OptimUM-02 data highlight continued progress across HLA-A*02:01-positive and -negative metastatic uveal melanoma.
Dr. Meredith McKean shares her perspective on the potential of these findings to help advance care for patients.
Uveal melanoma is distinct from cutaneous melanoma and requires a precision approach.
At IDEAYA, we’re advancing targeted research and clinical development.
Visit our booth at #ESMO26 or explore our pipeline to learn more: https://t.co/Igu4eHnZhw
#UvealMelanoma #PrecisionOncology
At #ESMO26, explore findings from IDEAYA’s clinical programs across uveal melanoma, small cell lung cancer and other neuroendocrine carcinomas.
View the OptimUM presentation schedule and details: https://t.co/VpDWIRn0Nb
#PrecisionMedicine
Visit IDEAYA at Booth #1013 during #ESMO26 to explore our precision medicine pipeline for hard-to-treat cancers.
Learn more about our science and pipeline: https://t.co/ExcLgGwn17
See you in Madrid!
#PrecisionOncology
This upcoming #ESMO26, join leading experts for an Industry Satellite Symposium on metastatic #UvealMelanoma and emerging treatment strategies.
View the official invitation and access details to listen in: https://t.co/sgemeR8nu3
Presented by Servier and developed with IDEAYA Biosciences.
What should people know about uveal melanoma?
Richard D. Carvajal, M.D. shares key context on this rare eye cancer and why understanding its presentation is an important first step in raising awareness.
Watch below.
#UvealMelanoma
The future of precision oncology starts with a deeper understanding of cancer biology.
Hear from Theo Ross, M.D., Ph.D. as she shares her perspective on how advances in cancer biology are shaping the future of precision medicine. Listen below.
#UvealMelanoma
What drives disease progression in uveal melanoma?
As researchers gain deeper insight into the molecular pathways underlying UM, new opportunities for innovation continue to emerge.
Learn more about the science behind UM: https://t.co/WKCcb79r6E
#UvealMelanoma
Behind every data point is a patient experience.
At a recent IDEAYA fireside chat, Ashley McCary, founder of Eye on Grace Foundation, shared her perspective on living with uveal melanoma and life beyond diagnosis.
Learn more at https://t.co/IykWmdDXv1
As #ASCO26 comes to a close, one thing is clear: the future of cancer care is full of possibility.
In a new IDEAYA Ideas blog, CCO Stu Dorman reflects on momentum in oncology, precision medicine, and innovation for patients.
Read more: https://t.co/lvIGjB0FZX
A great week at #ASCO26. Thank you to everyone who connected with our team. We're energized by the innovative science, meaningful conversations, and shared commitment to advancing precision medicine.
Thank you to everyone who met with our team.
#PrecisionMedicine
We’re proud to share the full results from the OptimUM-02 study in first-line HLA*A2-negative metastatic uveal melanoma.
Learn more: https://t.co/ef9FHcKhOO
#ASCO2026#UvealMelanoma
At IDEAYA, our robust pipeline reflects a focused commitment to precision medicine. From early discovery to late-stage development, we are advancing a portfolio focused on targeting the drivers of disease.
Learn more: https://t.co/MxTL1ov4tS
#PrecisionMedicine#Oncology#ASCO26